Investors can add all sorts of investments to an IRA, but many financial advisors will suggest sticking with conservative dividend stocks. The reason is simple — blue chip income generators generally bounce back from big market crashes, and the compounding effect of reinvested dividends can deliver massive returns over several decades.
At first glance, tobacco giant Altria (NYSE:MO) seems like a great stock for an IRA. Its flagship Marlboro brand dominates the U.S. market, it pays a hefty forward dividend yield of 3.4%, and it’s hiked that dividend every year since it spun off itsoverseas business as Philip Morris International (NYSE:PM) in 2008. But if you gaze further into Altria’s future, you’ll realize that it’s not a great long-term pick for your IRA at all.
Image source: Getty Images.
Why Altria seems like a good IRA stock
Altria shares have rallied 20% over the past 12 months, outperforming Philip Morris’ 15% rally but slightly underperforming the S&P 500’s 25% gain. Much of that growth can be attributed to two factors — a flight to high-yielding dividend stocks in a low interest rate environment and Altria’s purely domestic business insulating it from the currency headwinds which gobbled up Philip Morris’ overseas gains.
Top 10 Blue Chip Stocks To Buy Right Now: Yum! Brands, Inc.(YUM)
Advisors’ Opinion:
- [By Daniel B. Kline]
While its closest rivals Domino’s (NYSE:DPZ) and Papa John’s (NASDAQ:PZZA) have steadily delivered impressive growth in the United States Yum! Brands (NYSE:YUM) Pizza Hut has struggled.
- [By WWW.GURUFOCUS.COM]
McDonald’s is a fast-food service restaurant with more than 36 thousand restaurants in around 100 countries. With a market cap of $100 billion, the company has the largest position in the fast-food industry in the U.S., with Yum Brands (NYSE:YUM) being its closest competitor. The company sells burgers, fries and sandwiches with the vision of providing great taste, modern choices and real ingredients. McDonald’s is constantly trying to find new ways to strengthen the nutritional profile of its menu items while maintaining taste.
- [By Rich Duprey]
Yet pizza seems to be where real innovation is happening, because it’s not just Domino’s that has found success with digital technology, but Pizza Hut is alsobecoming a leader in showing just how far merchants can take artificial intelligence.The Yum! Brands (NYSE:YUM) pizza chain is still in the midst of a turnaround like the one Domino’s needed a few years back, and it is counting on technology to do it.
- [By WWW.THESTREET.COM]
As a tiebreaker, Cramer turned to Yum Brands (YUM) , where Pizza Hut also saw some softness, but was able to eek out an increase in gross margins.
Pizza delivery is the ultimate stay-at-home economy play, Cramer said, but clearly the rising tide is not lifting all boats, and only Domino’s is able to buck the trend with its superior technology initiatives.
- [By Wayne Duggan]
There has been a major movement toward antibiotic-free meat in fast-food restaurants in recent years. While a number of restaurants have switched to antibiotic-free chicken, McDonald’s and other restaurants are dragging their heels in switching to antibiotic-free pork and beef. Yum! Brands, Inc. (NYSE: YUM)’s KFC franchise is the latest chain to pledge to switch to antibiotic-free chicken.
Top 10 Blue Chip Stocks To Buy Right Now: Petroleo Brasileiro S.A.- Petrobras(PBR)
Advisors’ Opinion:
- [By Money Morning News Team]
Petroleo Brasileira SA Petrobras (NYSE ADR: PBR) is Brazil’s largest oil company and it’s our seventh best oil stock of 2016. Petrobras is an oil and natural gas exploration and production firm. It is also an operator of oil tankers, pipelines, and terminals in South America and globally.
- [By Paul Ausick]
Credit rating agency Standard & Poor’s on Friday raised its corporate credit rating on Petroleo Brasileiro S.A. (NYSE: PBR), commonly known as Petrobras, one notch, from B+ to BB-. The rating change does not lift Petrobras out of the non-investment grade category, but it lowers the risk from “highly speculative” to “speculative.”
- [By Craig Jones]
Alan Knuckman of Bulls-Eye Option said on Bloomberg Markets that he would buy Petroleo Brasileiro SA Petrobras (ADR)(NYSE: PBR), because it could benefit from the strength in crude oil.
- [By Chris Lange]
And Petroleo Brasileiro S.A. (NYSE: PBR), better known as Petrobras, is scheduled to release its most recent quarterly results Tuesday. The consensus estimates call for a net loss of $0.05 per share, as well as $18.05 million in revenue. Shares ended the weekat $8.91. The consensus price target is $11.22, and the 52-week range is $4.98 to $12.56.
- [By Chris Lange]
And Petroleo Brasileiro S.A. (NYSE: PBR), better known as Petrobras, is scheduled to release its most recent quarterly results late Thursday. The consensus estimates call for a profit of $0.16 per share, as well as $23.81 billion in revenue. Shares ended the weekat $8.86. The consensus price target is $10.82, and the 52-week range is $7.61 to $12.56.
Top 10 Blue Chip Stocks To Buy Right Now: Amgen Inc.(AMGN)
Advisors’ Opinion:
- [By WWW.THESTREET.COM]
Finally on Friday, Tiffany (TIF) reports, and Cramer is betting on positive news now that the company has an activist involved. He was also bullish on Amgen’s (AMGN) analyst meeting, saying investors should use any market weakness earlier in the week to buy.
- [By Chris Lange]
Amgen Inc. (NASDAQ: AMGN) saw its short interest increase to 7.78 million shares from the previous level of 7.38 million. Shares closed most recently at $145.34, in a 52-week trading range of $133.64 to $176.85.
- [By Maxx Chatsko]
Shares of Radius Health (NASDAQ:RDUS) rose over 20% Monday morning after Amgen (NASDAQ:AMGN) announced worrisome complications were discovered during a phase 3 trial for its osteoporosis drug candidate, Evenity. While the drug candidate met its primary endpoint in a more than 4,000-patient phase 3 study, a high rate of serious heart-related side effects were discovered. The drug was previously expected to gain marketing approval from the U.S. Food and Drug Administration in July, but that decision will now be delayed by up to a year or more, if the drug is approved at all.
Top 10 Blue Chip Stocks To Buy Right Now: BioDelivery Sciences International Inc.(BDSI)
Advisors’ Opinion:
- [By Jim Robertson]
On Friday, our Elite Opportunity Pronewsletter suggested small cap specialty pharmaceuticalstock BioDelivery Sciences International (NASDAQ: BDSI) as a bullish/long trade:
- [By Lisa Levin]
In trading on Tuesday, healthcare shares fell 0.48 percent. Meanwhile, top losers in the sector included MannKind Corporation (NASDAQ: MNKD), down 10 percent, and BioDelivery Sciences International, Inc. (NASDAQ: BDSI) down 10 percent.
Top 10 Blue Chip Stocks To Buy Right Now: Reinsurance Group of America, Incorporated(RGA)
Advisors’ Opinion:
- [By David Sterman]
My favorite insurers: AIG (NYSE: AIG) (which I discussed a few months ago), Protective Life (NYSE: PL) and Reinsurance Group of America (NYSE: RGA).
- [By Benzinga News Desk]
Morgan Stanley downgraded Chipotle (NYSE: CMG) to Equal-Weight.
UBS downgraded AMC Networks (NASDAQ: AMCX) to Sell.
Citi upgraded Sealed Air (NYSE: SEE) to Buy.
Goldman Sachs upgraded Reinsurance Group (NYSE: RGA) to Buy.
Top 10 Blue Chip Stocks To Buy Right Now: THERMOGENESIS Corp.(KOOL)
Advisors’ Opinion:
- [By Lee Jackson]
Cesca Therapeutics Inc. (NASDAQ: KOOL) had a 10% owner come in with a big-time purchase. Boyalfe bought a total of 6,102,942 shares of the stock a $2.52. The total for the purchase was posted at $6,838, 237.The company develops and manufactures automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. Its stock traded on Friday’s close at $3.45, so a well-timed buy.The 52-week range is $1.60 to $7.39. The consensus price targetis $2.
Top 10 Blue Chip Stocks To Buy Right Now: ProShares UltraShort Nasdaq Biotechnology(BIS)
Advisors’ Opinion:
- [By Jim Robertson]
Yesterday, our Elite Opportunity Pronewsletter suggested the ProShares UltraShort Nasdaq Biotech (NASDAQ: BIS) and Direxion Daily S&P Biotech Bear 3X Shares (NYSEARCA: LABD) as ways to short biotech onshort termweakness in the sector, but our suggestion comes with a long termcaveat:
Top 10 Blue Chip Stocks To Buy Right Now: Virtusa Corporation(VRTU)
Advisors’ Opinion:
- [By Lisa Levin]
Technology shares gained around 0.85 percent in trading on Friday. Meanwhile, top gainers in the sector included Virtusa Corporation (NASDAQ: VRTU), and Ceragon Networks Ltd (NASDAQ: CRNT).
Top 10 Blue Chip Stocks To Buy Right Now: Compass Diversified Holdings(CODI)
Advisors’ Opinion:
- [By WWW.MONEYSHOW.COM]
Compass Diversified Holdings (CODI) seeks to invest in manufacturing, distribution, consumer products, and business services sectors.
One thing I like about Compass is its strict definitions of its acquisition strategy. They have a six-step process of identifying companies to acquire that reads simply, but has lead to astounding success.
Top 10 Blue Chip Stocks To Buy Right Now: Veeva Systems Inc.(VEEV)
Advisors’ Opinion:
- [By Brian Stoffel]
To say that Veeva Systems (NYSE:VEEV) has performed well as a publicly traded company would be an understatement. While the stock itself is actually down since its post-IPO days, the company’s fundamentals have vastly improved during that time frame.
- [By Jim Robertson]
Today, our Elite Opportunity Pronewsletter suggested mid cap global life sciencescloud-based software solutions stock Veeva Systems Inc (NYSE: VEEV) as a bullish long trade for investors who have patience:
- [By Keith Speights, Brian Stoffel, and George Budwell]
Healthcare is changing rapidly. Which companies will emerge as the huge winners with these major changes? We asked three of our healthcare contributors to weigh in on the subject. Here’s whyAbbVie (NYSE:ABBV),Alphabet (NASDAQ:GOOGL) (NASDAQ:GOOG), Johnson & Johnson (NYSE:JNJ), and Veeva Systems (NYSE:VEEV) could represent bold bets on the future of healthcare.
- [By Peter Graham]
Mid cap global life sciencescloud-based software solutions stock Veeva Systems Inc (NYSE: VEEV) reported fiscal Q1 2018 earnings after the market closed yesterday with earningsbeating expectations. Total revenuesincreased 32% to$157.9 million as subscription services revenues rose 33% to $127.3 million whilenet incomeincreased 57% to $36.0million. The CEO commented:
